Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company, develops novel drugs to treat intractable diseases in the United States. The company utilizes its proprietary Dynamic Polyconjugate platform to develop targeted drugs based on the RNA interference mechanism that silences disease-causing genes. Its ARC-520, an RNAi-based therapeutic that is in Phase IIb clinical efficacy studies to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic, which is in Phase Ib clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. The company's pre-clinical stage drug candidates include ARC-521, an RNAi-based therapeutic for the treatment of chronic hepatitis B virus; ARC-F12, an RNAi-based therapeutic to treat hereditary angioedema and thromboembolic diseases; ARC-HIF2, an RNAi-based therapeutic to treat renal cell carcinoma; and ARC-LPA, an RNAi-based therapeutic for the treatment of cardiovascular diseases. It also holds patents related to Adipotide for the treatment of obesity and related metabolic disorders. The company has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
$5 support held and getting some good lift today. ARWR: Update on Financials for Fiscal Second Quarter Ended March 31, 2016 Total revenue for the fiscal second quarter (ARWR) was $43,750, as compared to $43,750 for the same period last year. Revenue was primarily related to licensed technology in both periods. R&D expenses for fiscal 2Q16 were $10 million, as compared to $21.8 million for fiscal 2Q15, which included an acquired in-process research and development cost of $10 million related to the acquisition of Novartis’ RNAi assets.
Great gains,... a bit late to start now,... based on the history,.. this one is ready for a correction.
